A detailed history of Engineers Gate Manager LP transactions in Xencor Inc stock. As of the latest transaction made, Engineers Gate Manager LP holds 46,671 shares of XNCR stock, worth $1.11 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
46,671
Previous 76,672 39.13%
Holding current value
$1.11 Million
Previous $1.45 Million 35.35%
% of portfolio
0.02%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$15.7 - $21.65 $471,015 - $649,521
-30,001 Reduced 39.13%
46,671 $938,000
Q2 2024

Aug 14, 2024

SELL
$18.21 - $24.5 $452,208 - $608,408
-24,833 Reduced 24.46%
76,672 $1.45 Million
Q1 2024

May 15, 2024

BUY
$18.65 - $26.52 $218,204 - $310,284
11,700 Added 13.03%
101,505 $2.25 Million
Q4 2023

Feb 14, 2024

BUY
$16.53 - $21.42 $1.3 Million - $1.69 Million
78,923 Added 725.26%
89,805 $1.91 Million
Q3 2023

Nov 14, 2023

BUY
$20.08 - $25.39 $41,987 - $53,090
2,091 Added 23.79%
10,882 $219,000
Q2 2023

Aug 14, 2023

BUY
$24.77 - $29.9 $217,753 - $262,850
8,791 New
8,791 $219,000
Q4 2022

Feb 14, 2023

BUY
$24.79 - $30.86 $252,560 - $314,401
10,188 New
10,188 $265,000
Q2 2022

Aug 15, 2022

BUY
$19.74 - $29.01 $243,394 - $357,693
12,330 New
12,330 $337,000
Q1 2022

May 16, 2022

SELL
$26.68 - $41.63 $318,132 - $496,396
-11,924 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$33.67 - $43.44 $401,481 - $517,978
11,924 New
11,924 $478,000
Q1 2020

May 15, 2020

SELL
$20.69 - $37.79 $315,688 - $576,599
-15,258 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$32.75 - $41.43 $499,699 - $632,138
15,258 New
15,258 $525,000

Others Institutions Holding XNCR

About Xencor Inc


  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.42B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Engineers Gate Manager LP Portfolio

Follow Engineers Gate Manager LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.